Oncorus

$16.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.64 (-3.75%) Today
-$0.11 (-0.67%) As of 12:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Oncorus and other stocks, options, and ETFs commission-free!

About ONCR

Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA. The listed name for ONCR is Oncorus, Inc. Common Stock.

CEO
Theodore T. Ashburn
Employees
—
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
414.50M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
377.08K
High Today
$17.10
Low Today
$16.03
Open Price
$17.02
Volume
197.92K
52 Week High
$37.86
52 Week Low
$14.60

ONCR Earnings

-$21.73
-$14.49
-$7.24
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 3, Pre-Market

You May Also Like

IEF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure